Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Norquist JM, Girman C, Fehnel S, Demuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.
Launois R, Le Moine JG, Huynh MT. Mixed treatment comparison, cost-effectiveness and budget impact analysis in the treatment of rheumatoid arthritis after failure of DMARD therapy: a comprehensive decision analytical modelling. Poster presented at the International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting; June 2, 2012. Washington, DC.
Poulos C, Hauber AB, Gonzalez JM, Ogale S, Turpcu A. Patient trade-offs between frequency and duration of biologic treatments for rheumatoid arthritis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. [abstract] Value Health. 2012 Jun; 15(4):A42.
Poulos C, Hauber AB, Gonzalez JM, Ogale S, Turpcu A. Patient trade-offs between frequency and duration of biologic treatments for rheumatoid arthritis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A42.
Le Moine JG, Launois R. Mixed treatment comparison, cost-effectiveness analysis and budget impact model in the treatment of rheumatoid arthritis after failure of conventional DMARD therapy using comprehensive Bayesian decision analytical modelling. Presented at the 3rd Joint CES/HESG Workshop; January 11, 2012. Aix-en-Provence, France.